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Abstract
Background: Since tumor growth requires reactivation of telomerase (hTERT), this enzyme is a challenging target
for drug development. Therefore, it is of great interest to identify telomerase expression and activity regulators.
Retinoids are well-known inducers of granulocytic maturation associated with hTERT repression in acute
promyelocytic leukemia (APL) blasts. In a maturation-resistant APL cell line, we have previously identified a new
pathway of retinoid-induced hTERT transcriptional repression independent of differentiation. Furthermore, we
reported the isolation of a cell variant resistant to this repression. Those cell lines could serve as unique tools to
identify new telomerase regulators.
Methods: Using a microarray approach we identified the long non-coding RNA, H19 as a potential candidate
playing a role in telomerase regulation. Expression of H19, hTERT, and hTR were examined by quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR). Telomerase activity was quantified by quantitative telomeric
repeats amplification protocol (qTRAP). In vitro and in vivo assays were performed to investigate H19 function on
telomerase expression and activity.
Results: We showed both in retinoid-treated cell lines and in APL patient cells an inverse relationship between the
expression of H19 and the expression and activity of hTERT. Exploring the mechanistic link between H19 and hTERT
regulation, we showed that H19 is able to impede telomerase function by disruption of the hTERT-hTR interaction.
Conclusions: This study identifies a new way of telomerase regulation through H19’s involvement and thereby
reveals a new function for this long non-coding RNA that can be targeted for therapeutic purpose.
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Background
Human telomerase is a special ribonucleoprotein
enzyme that stabilizes chromosome ends by adding
(TTAGGG)n telomeric sequences and thus has a key
role in maintaining telomere length and in cellular repli-
cative life-span. This ribonucleoprotein, usually absent
or expressed at a low level in most normal somatic cells,
is highly active in cancer cells, and plays a key role in
cell immortalization and tumorigenesis [1, 2]. Due to
this differential expression pattern, telomerase has been
proposed as a promising target for anticancer therapies.
Therefore, different therapeutic approaches for telomerase-
based treatment of cancer have been developed [3, 4]. The
main levels on which telomerase activity can be targeted
are associated with transcription of hTERT and hTR genes,
as well as disruption of the telomerase complex assembly,
inhibition of the assembled telomerase complex and its
interaction with telomeres [4].
Retinoids are well-known inducers of granulocytic mat-
uration of primary acute promyelocytic leukemia (APL)
blasts. Previous studies, including our own on the NB4
cellular model of APL, showed that hTERT repression is
associated with cell differentiation. In a maturation-
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resistant APL cell line (NB4-LR1), we showed that reti-
noids can regulate telomerase and telomere length inde-
pendently of cell maturation leading to growth arrest and
cell death [5, 6]. Moreover, we reported the isolation of a
variant of the NB4-LR1 cell line, named NB4-LR1SFD,
which is resistant to ATRA-induced cell death. In NB4-
LR1SFD cells, hTERT has been stably reactivated despite
the continuous presence of ATRA [7]. This stable
telomerase reactivation after an initial step of
downregulation seems similar to what occurs during
tumorigenesis when telomerase becomes reactivated.
Therefore, the NB4-LR1SFD cell line is a valuable cell
model to study the molecular events occurring during the
oncogenic reactivation of telomerase.
Using a microarray approach to identify genes differ-
entially modulated by ATRA treatment in NB4-LR1 and
NB4-LR1SFD cells, we found an inverse correlation
between the expression of hTERT and the long non-
coding RNA, H19. We set out to explore this potential
correlation and the underlying mechanistic link between
H19 expression and hTERT regulation and showed that
H19 is able to impede telomerase function by disrupting
the hTERT-hTR interaction. This finding identifies for
the first time a new way of telomerase regulation by
retinoids through H19’s involvement and thereby reveals
a new function of this long non-coding RNA.
Methods
Chemicals, cell lines, and cell cultures
All-trans retinoic acid (ATRA), 8-(4-chlorophenylthio)
adenosine 3′,5′-cyclic adenosine monophosphate (8-CPT-
cAMP), and protease inhibitor cocktail (P8340) were pur-
chased from Sigma (St Louis, MO, USA). The maturation
sensitive NB4 cells and both maturation-resistant human
APL cell lines, NB4-LR1 and NB4-LR1SFD, were cultured
as previously described [5]. The NB4-LR1SFD cell line was
isolated as a population of cells emerging from a culture
of NB4-LR1 cells under the selective presence of ATRA
(1 μM). It bypasses the death step induced by long-term
ATRA treatment because of the reactivation of
hTERT. The established NB4-LR1SFD cell line is stable
and able to grow either in the presence or in the
absence of ATRA. This property of resistance to
ATRA-induced cell death during a prolonged treat-
ment is maintained for more than 6 months of
culture in the absence of ATRA. Therefore both NB4-
LR1 and NB4-LR1SFD cells were routinely cultured in
the same ATRA-free RPMI medium.
All cells were cultured at 37 °C in a humidified
incubator with 5% CO2 (Binder Incubators, Nanterre,
France). Cell density was determined every 2 or
3 days using Coulter counting, and when it reached
6-7 × 105 cells/ml, cells were re-seeded in a new flask
containing fresh medium.
RNA extraction and processing for microarray
experiments
NB4-LR1 and NB4-LR1SFD cells were treated or not for
7 days with ATRA (1 μM). Total cellular RNA from 3
independent experiments (biological replicates) was
extracted using TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions. After validation of the
RNA quality with Bioanalyzer 2100 (using Agilent
RNA6000 nano chip kit), 500 ng of total RNA was reverse
transcribed following the GeneChip® WT Plus Reagent Kit
(Affymetrix) instructions. Briefly, the resulting double
strand cDNA is used for in vitro transcription with T7
RNA polymerase (all these steps are included in the WT
cDNA synthesis and amplification kit of Affymetrix).
After purification according to Affymetrix protocol, 5.5 μg
of the cDNA obtained are fragmented and biotin-labeled
using Terminal Transferase (using the WT terminal
labeling kit of Affymetrix). cDNA is then hybridized to
GeneChip™ Human Transcriptome Array 2.0 (HTA 2.0.)
(Affymetrix) at 45 °C for 17 h.
After overnight hybridization, chips were washed on
the fluidic station FS450 following specific protocols
(Affymetrix) and scanned using the GCS3000 7G. The
scanned images were then analyzed with Expression
Console software (Affymetrix) to obtain raw data (CEL
files) and metrics for Quality Controls. The observations
of some of these metrics and the study of the distribu-
tion of raw data show no outlier experiments. CEL files
were then normalized and processed to signal intensities
using the RMA (robust multi-array average) algorithm
from the Bioconductor library and the cdf file V20 from
BrainArray. All subsequent analyses were done on the
log (base 2) transformed data in Partek Genomics Suite:
non supervised analysis and analysis of variance
(ANOVA) were used to detect eventual outlier samples
and to identify differentially expressed genes. A global
view of the differentially expressed genes was drawn using
a Volcano Plot, the log transformed adjusted p-values
plotted on the y-axis and log2 fold change values on the
x-axis. A cut-off value of p < 0.01 was chosen for statistical
significance. The expression of the significant genes was
displayed in a heatmap. The statistically significant
differential gene expression list was further trimmed by con-
sidering only genes with│fold change│ > 2 as biologically
significant. Venn diagrams were generated using Venny tool
(http://bioinfogp.cnb.csic.es/tools/venny/index.html).
Quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
Total RNA was isolated from cells as mentioned above.
RNA concentration and quality were determined via
A260/230 and A260/A280 nm absorbance with Nano-
drop Spectrophotometer. One microgram of total RNA
was subjected to reverse transcriptase (RT) reaction
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using Transcriptor First Strand cDNA Synthesis kit
(Roche Diagnostics) according to the manufacturer’s in-
structions with random hexamer primers. The cDNAs
were subsequently analyzed by quantitative real-time
PCR using the LightCycler technology and the Light
Cycler FastStart DNA MasterPLUS SYBR Green Kit
(Roche Diagnostics) according to the manufacturer’s in-
structions. hTERT, hTR and H19 levels were normalized
to the expression of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) serving as the internal control
gene. Primer sequences are shown in Additional file 1:
Table S1. All samples were analyzed in triplicate in at least
three independent experiments.
Quantitative RT- PCR for detection of miR-675-5p and
miR-675-3p
Total RNA was extracted as previously described. The
expression of miR-675-5p and miR-675-3p was quanti-
fied by quantitative RT-PCR. Single strand RNA is first
polyadenylated by poly(A)polymerase before reverse
transcription into cDNA using qScript RT with a propri-
etary adapter oligo(dT) primer. Using the kit: “the
qScript microRNA cDNA Synthesis Kit” (Quanta Biosci-
ences, VWR), following the manufacturer’s protocol. The
step of amplification was carried out using the LightCy-
cler technology, the PerfecCTa microRNA Assay, the
PerfeCTa Universal PCR Primer and miRNA specific
primers (Quanta Biosciences). SNORD44 serves as an
internal control. The miRNA specific primers are listed
in Additional file 1: Table S1.
Production of RNA molecules for in vitro studies
Plasmids pcDNA 3.1(+)-H19 and pcDNA 3.1(+)-GFP
(green fluorescent protein, used in control experiments)
were linearized with the restriction enzyme BamH1
(20 U/μl). The products of digestion were purified using
the plasmid DNA purification kit (Nucleobond® PC20,
Macherey Nagel) and used as templates for subsequent
in vitro transcription. H19 and GFP RNA molecules
were generated by in vitro transcription using the T7
RNA polymerase (Roche). The reaction was performed
in a final volume of 20 μl containing 1 μg of linearized
plasmid, 1× reaction buffer (40 mM Tris, pH 8.0, 6 mM
MgCl2, 2 mM spermidine, 10 mM DTT, 10 mM each
ATP, GTP, UTP, and CTP, 1 μl RNase inhibitor (20 U/μl)
, and 2 μl T7 RNA polymerase (20 U/μl). The reaction
mix was incubated at 37 °C for 2 h before treatment
with RNase-free DNase I (1 U/μl, Promega) at 37 °C for
30 min and the reaction was terminated by adding 2 μl
0.2 M EDTA and heating at 65 °C for 10 min. In
vitro transcribed products were separated from unincor-
porated nucleotides with the RNeasy Mini kit (Qiagen)
and stored at − 80° until used.
Measurement of telomerase activity
Samples for telomerase activity assays were extracted
following standard protocols. Briefly, cell pellets were
resuspended (106 cells in 200 μl) in lysis buffer (3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane-sulfonate,
10 mM Tris pH 8.0) and incubated on ice for 30 min. After
centrifugation at 16000 g for 20 min. at 4 °C, aliquots of the
supernatant were rapidly frozen and stored at − 80 °C. The
protein concentration of extracts was determined with the
BCA Protein Assay (Thermo Scientific).
Real-time quantitative telomeric repeat amplification
protocol (qTRAP) assay was performed as described [8].
Briefly, reactions were carried out in 20-μl with LightCy-
cler® FastStart DNA Master SYBR Green I (Roche) with
0.1 μg of telomerase primer TS, 0.05 μg of reverse pri-
mer ACX, and 2 μl of the sample to be tested. Samples
were incubated 30 min. at 37 °C, 10 min. at 95 °C and amp-
lified for 40 PCR cycles (5 s at 95 °C and 60 s at 60 °C).
Data analysis was performed with the LightCycler software
that integrates the real-time PCR efficiency that was calcu-
lated by serial dilution of the most active sample. Primer se-
quences are shown in Additional file 1: Table S1.
In vitro qTRAP was designed to test whether H19
RNA fragments would inhibit telomerase enzymatic ac-
tivity in vitro. Cell extracts (1 μg of protein) were mixed
with the indicated amount of in vitro transcribed H19 or
GFP RNA and telomerase activity was quantified using
the qTRAP assay as described above.
Nucleofection of DNA constructs
Transfections were performed using the Amaxa Nucleo-
fector technology. NB4 cells were transfected using 2 μg
of either pcDNA 3.1 (+)-H19 or pcDNA 3.1 (+)-empty
vector, using transfection solution V and program 001,
according to the manufacturer’s instructions. Six hours
after transfection, RNA and proteins were extracted as
previously described. H19 and hTERT levels were quan-
tified by qRT-PCR, telomerase activity was measured
using qTRAP assay as described above.
Immunoprecipitation (IP) of hTERT-hTR complexes
To prepare the antibody-coated beads, 30 μl of protein
A/G magnetic beads (Thermo Scientific) were incubated
with 4 μg of polyclonal anti-hTERT antibodies or 4 μg of
rabbit pre-immune IgG in 150 μl IP buffer (1% Igepal CA-
630, 137 mM NaCl, 20 mM Tris-HCl at pH 8.0, 10%
glycerol, and 2 mM EDTA) at 4 °C for at least 2 h. Then,
the beads were washed three times with IP buffer and kept
on ice until used. To prepare cell lysates, cells were
harvested by centrifugation at 220 g and cell pellets re-
suspended in 300 μl of freshly prepared lysis buffer (0.5%
Na deoxycholate, 1% IGEPAL CA-630, 0.1% SDS,
150 mM NaCl, 50 mM Tris-HCl at pH 7.8, 10 mM EDTA,
1 × protease inhibitor cocktail, 1 mM PMSF, 5 mM NaF,
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1 mM sodium orthovanadate, and 4 U/μl RNase inhibi-
tor). The suspensions were incubated on ice for 20 min.
After removing insoluble materials by centrifugation, ly-
sates were transferred to tubes containing hTERTantibody
(Rockland) or pre-immune IgG-coated beads, and IP was
carried out by rotating the tubes at 4 °C overnight. Beads
were then washed briefly three times and RNAs were eluted
by incubating the beads in 100 μl buffer (20 mMTris-HCl
pH 8.0, 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM
EDTA) containing 0.8% SDS and 1.2 g/l Proteinase K, dur-
ing 30 min. at 55 °C with shaking. Eluted beads were dis-
carded using a magnet and the supernatant processed with
TRIzol reagent. The resulting RNA preparations were ana-
lyzed for the presence of hTR by quantitative RT-PCR as de-
scribed above.
In some experiments, 10 μg of in vitro transcribed
H19 RNA molecules were preincubated with 100 μg of
cellular extracts for 30 min. at room temperature. This
mixture was added to tubes containing hTERT antibody,
and IP was carried out by rotating the tubes at room
temperature for 90 min. The samples were then proc-
essed as above for hTR quantification. As a control, an
in vitro transcribed GFP RNA was used.
Statistical analysis
Statistical analysis was conducted using GraphPad Prism
6.01 software. The difference between groups was ana-
lyzed using unpaired or paired Student’s t-test when
there were only two groups or assessed by one-way
ANOVA followed by the Tukey’s multiple comparison
tests when there were more than two groups. All tests
carried out were two-tailed. Differences were considered
as significant when p < 0.05.
Results
The induction of H19 expression by ATRA treatment of
the maturation resistant NB4-LR1 and NB4-LR1SFD cells is
associated with hTERT repression
A transcriptomic analysis on microarray was performed
on the two ATRA-induced maturation-resistant NB4-LR1
and NB4-LR1SFD cell lines to identify genes differentially
expressed upon ATRA treatment. We isolated total RNAs
from ATRA-treated or non-treated cells NB4-LR1 and
NB4-LR1SFD cells. Day 7 was chosen because, at this time
of treatment, the hTERT expression level was reduced in
NB4-LR1 cells (to about 90% of the non-treated cells),
whereas it was stabilized in NB4-LR1SFD cells (at about
60% of the non-treated cells) (Fig. 1a).
Transcriptome profiling identified in NB4-LR1 cells, 256
genes that were differentially expressed between ATRA-
treated and non-treated cells. Among these, 183 were up-
regulated and 73 were downregulated. In NB4-LR1SFD
cells, only 65 genes were differentially expressed between
treated and non-treated cells. Among them, 25 were
downregulated whereas 40 were upregulated (Add-
itional file 2: Table S2). The differentially expressed genes
were visualized in the form of a volcano plot (Fig. 1b). The
expression of the significant genes was displayed in a heat-
map (Fig. 1c). Venn diagram representation (Fig. 1d) show-
ing the overlap between genes up- or down-regulated in
NB4-LR1 treated vs control cells and NB4-LR1SFD treated
vs control cells enabled us to focus our attention on H19
gene, coding a long non-coding RNA, because it is the only
gene whose expression was induced after ATRA treatment
in NB4-LR1 cells but repressed in NB4-LR1SFD cells
exposed to the same treatment.
To validate this observation, qRT-PCR was performed to
investigate H19 expressions in NB4-LR1 and NB4-LR1SFD
cells treated with ATRA (1 μM) for different times.
Figure 2a showed that the constitutive H19 expression is
higher in NB4-LR1SFD than in NB4-LR1 cells. The expres-
sion of hTR and hTERT RNA were also higher in NB4-
LR1SFD compared to NB4-LR1 cells, which is consistent
with a difference in telomerase activity. In NB4-LR1 cells,
ATRA treatment induced a strong increase in the expres-
sion of H19 associated with a progressive decrease of
hTERT expression. In contrast, in the NB4-LR1SFD cell
line, as already reported in Fig. 1a, despite the continuous
presence of ATRA, a high level of hTERT mRNA (more
than 50% of expression compared to the untreated cells) of
control expression) and telomerase activity was
maintained. This partial resistance to ATRA-induced
hTERT repression was associated with an important de-
crease of H19 expression after a slight but significant in-
crease (Fig. 2b). Note that hTR expression level was not
modified upon ATRA treatment in both cell lines.
We have previously shown that hTERT repression by
prolonged ATRA treatment was reversible [5]. Similarly,
in both NB4-LR1 and NB4-LR1SFD cells, the effects of
ATRA treatments on H19 expression were reversible
(Fig. 3a). Indeed, the withdrawal of ATRA from cell
cultures at day 8 induced a complete (NB4-LR1) or
partial return (NB4-LR1SFD) of H19 expression to the
baseline level before ATRA treatment. In parallel,
hTERT expression is nearly (NB4-LR1) or completely
restored (NB4-LR1SFD) in cells after ATRA removal. It is
worthy to mention, as previously noticed, that hTR
expression level remained unchanged as compared with
the control cells throughout the experiment.
The NB4-LR1SFD cell line was generated after a
prolonged culture of NB4-LR1 cells under the select-
ive presence of ATRA [7]. This cell line that has been
established as a permanent cell line, overcomes the
death induced through a telomere-dependent pathway,
proliferates, and expresses high levels of telomerase
despite continuous ATRA treatment (Figs. 1a and 2b).
We performed a new similar experiment on NB4-LR1
cells in order to investigate H19 expression during
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the procedure of selection of resistant cells to ATRA-
induced hTERT repression. As previously observed
[7], many attempts failed and cells died upon ATRA
prolonged exposure. However, in two separate experi-
ments, a population of cells emerged from the culture
by day 50. Examination of hTERT and H19 expres-
sions revealed that the high repression of hTERT dur-
ing the first 5 weeks of treatment was associated with
a high increase of H19 expression (Fig. 3b). However,
around day 50, when most of the cells progressed to-
ward the death we observed a rapid decrease of H19
expression and the re-expression of hTERT associated
with recovered cell growth despite the continuous
presence of ATRA.
H19 encodes two conserved miRNAs processed from
its first exon, miR-676-5p and miR-675-3p [9]. Using
several in silico bioinformatics web-based analysis in-
cluding TargetScan (URL:http://www.targetscan.org),
RNA22 (URL: https://cm.jefferson.edu/rna22), and
miRanda (URL:https://omictools.com/miranda-tool),
we found that hTERT mRNA was predicted as a po-
tential, target of miR-675-5p, although poorly con-
served. Therefore, we investigated the expression of
this miRNA in both cell lines before and after ATRA
treatment (Additional file 3: Figure S1a and b). The
expression of miR-675-5p did not exhibit any sig-
nificant difference either before or after ATRA treat-
ment of NB4-LR1 and NB4-LR1SFD. Of note only a
a d
b
c
Fig. 1 Microarray-based expression profiling. a Kinetics of hTERT expression in NB4-LR1 and NB4-LR1SFD cells treated with ATRA (1 μM). b Volcano
plot representation of the differentially expressed genes in a pair wise comparison of NB4-LR1 (left panel) and NB4-LR1SFD (right panel) cells
treated with ATRA (1 μM) for 7 days. The plot indicates -log10 (p-value) for genome-wide genes (Y-axis) plotted against their respective log2
(fold change) (X-axis). The significant cut-off was set to a p-value of 0.01 (−log10 (p-value) ≥ − 2, horizontal line), the biological cut-off was set to a
fold change of ±2 fold (log2(fold change) < − 1 and > + 1, vertical lines). In ATRA-treated vs non-treated NB4-LR1 cells (left panel) biological and
statistically insignificant genes are presented in black. A color was attributed to each gene whether it is significantly up-regulated (red) or
down-regulated (blue). A star indicates hTERT and H19 genes in blue and red, respectively. Importantly, in the NB4-LR1SFD right panel, all genes
retained the color defined in the NB4-LR1 left panel. Therefore H19, in red in the NB4-LR1 Volcano panel, remained in red in the NB4-LR1SFD Volcano
panel, even though its expression was repressed. c Heat map of expression profiles of genes that were differentially expressed in NB4-LR1 compared
to NB4-LR1SFD ATRA-treated cells. Red indicates upregulated genes and green indicates downregulated genes d Venn diagrams showing the number
of significantly differentially expressed genes (up-regulated and down-regulated) at 7 days of ATRA treatment (1 μM) in NB4-LR1 and NB4-LR1SFD.
Figures in the overlapping sections indicate the number of differentially expressed genes common to multiple pair-wise cell lines comparison. H19 is
the only gene to be up-regulated in NB4-LR1 ATRA-treated cells but down-regulated in the NB4-LR1SFD cells after ATRA treatment. Lists of
corresponding genes are presented in Additional file 2 (Table S2)
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significant increase of miR-675-3p expression was ob-
served in ATRA-treated NB4-LR1 cells.
H19 expression is induced in the NB4-LR1SFD cells by
alternative treatments that repress hTERT expression and
decrease telomerase activity
In contrast with the parental NB4 cells that are sensitive
to ATRA-induced maturation, both NB4-LR1 and NB4-
LR1SFD cell variants fail to mature upon ATRA
treatment alone. However, maturation can be rapidly
induced following the cooperative stimulation by ATRA
and cAMP analog [7, 10]. This maturation has been
associated with hTERT repression and a decrease of
telomerase activity. Therefore, the expression of H19
was measured in NB4-LR1SFD cells during the induction
of maturation by the combination of ATRA and the
cAMP analog, 8-CPT-cAMP. As shown in Fig. 4a, this
combination induced in the NB4-LR1SFD cells an increase
of H19 expression associated with a maturation-
dependent repression of hTERT. Of note, 8-CPT-cAMP
treatment alone induced a strong increase of H19 expres-
sion. This increase was accompanied with a reduction of
hTERT mRNA level similar to that seen after ATRA treat-
ment (about 30%). However, 8-CPT-cAMP treatment of
these cells induced also a reduction of telomerase activity
not observed after ATRA treatment. This suggests that
the decrease of telomerase activity cannot be explained by
hTERT repression alone. Considering that arsenic trioxide
(As2O3) combined with ATRA is also able to repress
hTERT in the NB4-LR1SFD cells [11], we conducted an
experiment to determine whether this combination affects
also H19 expression. As previously shown, we observed
a b
Fig. 2 H19 is induced upon ATRA treatment in NB4-LR1 cells in association with hTERT repression, whereas it is repressed in the NB4-LR1SFD cells
resistant to ATRA-induced hTERT repression. a Basal expression levels of H19, hTR, and hTERT mRNA and relative telomere activity (RTA) in NB4-LR1
and NB4-LR1SFD cells. b Expression levels of H19, hTR, and hTERT mRNA and RTA after treatment of NB4-LR1 and NB4-LR1SFD cells with ATRA
(1 μM) for the indicated time. All experiments were repeated at least 3 times. Expression levels were normalized to GAPDH expression. RTA
measured by qTRAP as described in “Methods” is expressed as the percentage of that detected in the untreated cells. Results were expressed as
means +/− SEM. t-test (a) or one way ANOVA with post-hoc Tukey, ns p > 0.05, *p < 0.05, **p < 0.001, ***p < 0.001
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that, in NB4-LR1SFD cells, this combined treatment
induced a repression of hTERT (Fig. 4b). Moreover, this
repression was associated with an increased H19
expression. The treatment with As2O3 alone changed
neither expressions of H19, hTERT and hTR nor activity of
telomerase. Altogether, these observations demonstrate
that, in the NB4-LR1SFD cells, different treatments that
increase H19 expression lead to a decrease of telomerase
activity associated to a certain extent with hTERT gene
repression.
An inverse correlation between the expressions of hTERT
and H19 is observed in APL patients
Given the above results demonstrating, in the APL cellu-
lar model, an inverse correlation between H19 and
hTERT expression levels, we wondered whether this cor-
relation could be found also in APL patient cells.
Therefore, we analyzed the expression levels of hTERT
and H19 using publicly accessible expression profiles of
16 APL patients (TCGA, http://cbioportal.org). As indi-
cated in Fig. 5, there was a negative correlation between
H19 and hTERT expressions in these patients (r = − 0.500,
p < 0.05). This observation reinforces the idea that there is
a link between H19 and hTERT.
H19 LncRNA inhibits telomerase activity
To examine an effect of H19 on hTERT expression or
telomerase activity independently of ATRA treatment,
we performed a transient overexpression of H19. This
experiment was performed on the parental NB4 cells
since in these cells transfection is much more efficient
and much less toxic than in NB4-LR1 and NB4-LR1SFD
cell sublines. The results in Fig. 6a indicate that H19
overexpression in NB4 cells led to a significant decrease
a b
Fig. 3 a The effects of ATRA treatment on H19 expression are reversible in both NB4-LR1 and NB4-LR1SFD. After culturing cells for 8 days in the
presence of ATRA (1 μM), the NB4-LR1 cell culture was switched to ATRA-free medium. (− 7) refers to the NB4-LR1 cells that were cultured 7 days
after ATRA removal. Expression levels of H19, hTERT mRNA, and hTR were quantified and normalized to GAPDH expression. Results were expressed
as means +/− SEM. One way ANOVA with post-hoc Tukey, ns p > 0.05, *p < 0.05, ***p < 0.001, ****p < 0.0001. b Establishment of an NB4-LR1SFD
like cell line from NB4-LR1 cell line cultured in the continuous presence of ATRA (1 μM). By day 50, in several experiments, most of the cells
underwent cell death. However, in two separate experiments a new population, similar to the NB4-LR1SFD, overcame this cell death step. The
lower panel shows the population doublings of one of the two cultures. At the indicated times, RNA was extracted and hTERT, H19, and hTR
expressions measured. Expression levels were normalized to GAPDH expression. Note from day 53 the decrease of H19 expression (upper panel)
associated with hTERT re-expression (middle panel) t-test or one way ANOVA with post-hoc Tukey, ns p > 0.05, *p < 0.05, ***p < 0.001. ****p < 0.0001
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of telomerase activity measured by TRAP assay
compared to NB4 cells transfected with empty pcDNA
3.1(+) vector, whereas no significant change in neither
hTERT mRNA nor in hTR levels was observed.
To explore further the interfering effect of H19 on tel-
omerase activity, we performed a qTRAP assay in cell
extracts from NB4-LR1 cells incubated with increasing
amounts of in vitro transcribed H19 RNA. Figure 6b
shows that incubation with H19 RNA produced a
marked inhibition of the telomerase activity present in
cell extracts from NB4-LR1 cells. The inability of the
irrelevant GFP RNA to inhibit telomerase activity
demonstrated this selectivity. The inhibitory effect of
H19 on telomerase activity is also observed when incu-
bation was performed using NB4-LR1SFD cell lysates.
Taken together, these data indicate that H19 transcribed
in vivo or in vitro could inhibit telomerase activity.
H19 promotes telomerase inhibition by affecting the
assembled telomerase complex
Human telomerase is an RNA binding protein that con-
sists at least of two core subunits, hTERT protein and a
template RNA subunit (hTR). Both hTERT and hTR are
essential for the assembly of a functional active telomer-
ase in vitro and in vivo [12]. Therefore, we hypothesized
that one possible mechanism by which H19 can inhibit
telomerase activity might be through its influence on the
proper telomerase assembly into a functional complex
and might involve hTR. To explore this assumption, we
performed RNA immunoprecipitations (RIP) on lysates
from NB4-LR1 or NB4-LR1SFD cells treated or not with
ATRA (1 μM) for 48 h with an anti-hTERT antibody or
a normal rabbit IgG, and measured by qRT-PCR the
amount of hTR in the pellet fraction of the immunopre-
cipitation reactions. The antibody against hTERT has
already been previously validated [13] and was further
verified (Additional file 4: Figure S2). Only the hTR
bound to hTERT can be recovered in the immune com-
plex. Figure 6c shows that hTR level was lower in the
immunoprecipitates from NB4-LR1 cells treated with
ATRA relative to non-treated NB4-LR1 cells. To further
investigate a direct role of H19 on telomerase activity a
Fig. 4 H19 expression is induced in the NB4-LR1SFD cells by
alternative treatments. Expression levels of H19, hTERT, and hTR and
telomerase activity after treatment of NB4-LR1SFD cells for 48 h with
ATRA (1 μM) alone or in combination with either 8-CPT-cAMP
(100 μM) or Arsenic trioxide (As2O3, 0.2 μM).. Expression levels were
normalized to GAPDH expression. Results were expressed as means
+/− SEM. t-test or one way ANOVA with post-hoc Tukey, *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001
Fig. 5 Negative correlation between the expression of hTERT and
H19 in acute promyelocytic leukemia patients. The correlation
analysis of H19 and hTERT expression was performed using the
Pearson correlation test with the software of GraphPad Prism 6.01
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complementary experiment was performed using lysates
from NB4-LR1 cells supplemented with either the H19
RNA or an irrelevant GFP RNA, and then subjected to
immunoprecipitation. Figure 6d shows that the lysate
supplementation with H19 decreased the amount of hTR
immunoprecipitated with hTERT. As a control for speci-
ficity, we added the irrelevant GFP RNA in cell lysate
and showed no significant changes in the amount of
hTR in the hTERT immunoprecipitate.
Discussion
In this study, using a pair of well-established cell lines that
respond differently to ATRA treatment in terms of tel-
omerase expression, we identified a new pathway through
which ATRA can regulate telomerase activity. This new
pathway involves H19, a long non-coding RNA.
We have previously shown that in the maturation re-
sistant NB4-LR1 APL cells, ATRA induced a strong
transcriptional repression of hTERT gene expression in
the absence of cell differentiation. In the present study,
we demonstrated that in parallel, ATRA induces a
marked increase of H19 expression. In contrast, in the
NB4-LR1SFD cell line, which in addition is resistant to
ATRA-induced repression of hTERT, ATRA treatment
induced a repression of H19. Importantly, treatments of
these cells with ATRA combined to either cAMP ana-
logs (to activate PKA signaling pathway and induce dif-
ferentiation) or arsenic trioxide induced H19. In both
cases of treatments, the increase of H19 levels occurs in
parallel with the repression of hTERT suggesting an in-
verse relationship between H19 and hTERT expression
at the level of the RNA. The precise events downstream
of ATRA that result in H19 induction are not known
and requires further investigation. An induction of H19
transcription by ATRA has already been described in
cells derived from human testicular germ tumors associ-
ated with growth inhibition [14]. Notably, exploring the
AML patient cohort from TCGA atlas, we found the same
a
b
c
d
Fig. 6 H19 RNA inhibits telomerase activity by altering the assembled telomerase complex. a Influence of H19 overexpression on hTR and hTERT
expression and telomerase activity. NB4 cells were submitted to nucleofection in the presence of H19 (H19-pcDNA) or empty vector (pcDNA). Six
hours after nucleofection, proteins and RNA were extracted. The levels of H19, hTR RNA, and hTERT mRNA were quantified by qRT-PCR and normalized
to the levels of GAPDH mRNA. RTA was measured by qTRAP. b In vitro concentration-dependent inhibition of telomerase activity by H19. NB4-LR1 cells
were extracted with CHAPS buffer. In vitro transcribed H19 was incubated with protein extracts for 90 min. Before assessment of telomerase activity. In
vitro transcribed GFP was included as a specificity control. RTA measured by qTRAP is expressed as the percentage of that detected in protein extracts
not supplemented with RNA molecules. c Lysates prepared from NB4-LR1 and NB4-LR1SFD cells treated or not with ATRA (1 μM) for 48 h were
subjected to immunoprecipitation (IP) with IgG or anti-hTERT antibodies. The immunoprecipitates were extracted for hTR analysis by quantitative
RT-PCR. d Lysates from non-treated NB4-LR1 cells were preincubated with in vitro transcribed H19 RNA molecules subjected to IP using the hTERT
antibody. The immunoprecipitates were then incubated for 90 min. Co-precipitated RNA were extracted and hTR assembled with hTERT quantified by
qRT-PCR. As a control, an in vitro transcribed GFP RNA was used. Results were expressed as means +/− SEM. t-test or two way ANOVA *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001
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inverse relationship in the subgroup of APL patient. Even
though this subgroup included only 16 patients, taken to-
gether these data strongly suggest an inverse relationship
between the expression of hTERT and H19.
Long non-coding RNAs (LncRNAs) have recently
emerged as a novel group of non-coding RNAs able to
regulate mammalian gene expression. Besides their par-
ticipation in normal physiology, LncRNA have been im-
plicated in cancer development and progression [15, 16].
H19, an oncofetal gene that does not code for a pro-
tein, is transcribed to a non-coding RNA. It is located
on human chromosome 11p15.5 within the highly
conserved imprinted H19/insulin-like growth factor 2
(IGF2) locus. These two genes are reciprocally
imprinted, leading to differential allelic expression of
H19 from the maternal allele and IGF2 from the paternal
allele [17]. Although H19 has been intensively studied in
genomic imprinting, the function of H19 as a non-
coding RNA has only recently begun to be investigated
[18]. H19 was initially identified as a tumor suppressor.
Indeed, its overexpression in some tumor cells was asso-
ciated with inhibition of proliferation, morphological
changes, decrease of clonogenicity in soft agar, and
tumorigenicity in nude mice [19]. Furthermore, down-
regulation of H19 gene expression was recognized as an
early event in the formation of several tumor types [20–
22]. However, increased expression of H19 has also been
observed in a variety of tumors, suggesting that H19 is,
in contrast, essential for tumor growth [23–29]. A link
has been well established between H19 and several
tumorigenesis related genes, such as c-Myc and E2F1
[30, 31]. Thus, it remains controversial as to whether
H19 functions as a tumor promoter or a tumor suppres-
sor. It is possible that H19 plays differential roles de-
pending on the developmental stage and/or the tissue
type. The investigations on H19 functions were more
widely depicted in solid tumors than in leukemia. In
addition, the exact mechanism by which H19 as a non-
coding RNA functions remain to be elucidated. Long
non-coding RNA, including H19 can directly modulate
the transcription of its target genes either by recruitment
of chromatin modifiers or sequestration of regulatory
proteins or regulate mRNA degradation and translation
[32–36]. We have previously shown that epigenetic
modifications targeting the distal region of hTERT pro-
moter could account for the capacity of retinoids to re-
press hTERT [37]. However, investigations using
invalidation and overexpression experiments failed to re-
veal any direct effect of H19 on hTERT expression,
which made it unlikely that H19 could have a direct ef-
fect on hTERT expression independently of ATRA
treatment.
H19 as a primary miRNA transcript generates two ma-
ture miRNAs, miR-675-3p and miR-675-5p [9]. These
two conserved miRNAs play important roles in the regu-
lation of H19-mediated processes. H19 could, therefore,
at least in part, function through these miRNAs. Using
bioinformatics miRNA target prediction software indi-
cated hTERT mRNA as a potential, although poorly con-
served, target of miR-675-5p. However, no significant
change of the expression of miR-675-5p was observed dur-
ing ATRA treatment of NB4-LR1 cells, which makes it un-
likely a direct action of this miRNA on hTERT mRNA level.
Many LncRNA, including H19, participate in molecu-
lar regulation pathways through their interactions with
proteins and modulation of their activities [38]. Tel-
omerase enzyme is unusual: it has a protein component
that has an affinity for hTR, its natural RNA partner es-
sential for its activity. Using an in vitro telomerase assay,
we observed that the addition of in vitro transcribed
H19 RNA molecules to protein extracts prepared from
either NB4-LR1 or NB4-LR1SFD cells inhibited
telomerase activity. Furthermore, we demonstrated that
the ectopic expression of H19 in NB4 cells induced a
decrease of telomerase activity without any modifications
of hTERT expression indicating that the mechanism of
action might involve hTR. This hypothesis was further
supported by the observation that 8-CPT-cAMP treat-
ment can induce alone an important increase of H19 asso-
ciated with a notable loss of telomerase activity whereas
hTERT expression remained relatively high. Using RIP ex-
periments, we showed that H19 decreases the amount of
hTR associated with hTERT component and thereby im-
pairs the functions of this enzyme. We were not able to
demonstrate a direct interaction of H19 with either
hTERT protein or its RNA component hTR. Indeed, the
amount of hTERT in a cell is very low [39] and western
blot are not sensitive enough to detect the endogenous
protein. It is likely that H19 does not bind tightly the tel-
omerase ribonucleoprotein but instead is recruited either
transitorily or through another telomerase auxiliary factor.
The interaction of hTERT with another RNA component
different from hTR has already been reported. Indeed,
using a tandem affinity peptide-tagged hTERT protein in
Hela S3 cells, Maida et al. identified a heterogeneous mix-
ture of 38 RNA sequences associated with hTERT, includ-
ing the RNA component of mitochondrial RNA
processing endoribonuclease (RMRP) [40]. TERT has also
been reported to interact with mitochondrial tRNAs and
amino-acylo tRNA synthases [41]. Another possible
mechanism for the decrease of hTR binding to hTERT
protein is the H19 interference with free hTR preventing it
from associating with hTERT.
Our results contrast with those previously published
[42] showing that overexpression of H19 enhances the
binding of hTERT to hTR and leads to an increase of tel-
omerase activity. In this study, Pu et al. provided no in-
formation regarding the hTERT antibody used in the RIP
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experiment performed. However, the lack of specificity
of most commercially available antibodies directed
against the hTERT protein is well-known within the sci-
entific community in this field [13]. The specificity of
the antibody used here has already been well character-
ized [13] and further verified in the present work. Another
explanation for such discrepancy is the difference in the
cellular model used in their study (liver cancer stem cells).
One possibility is that, H19 could be a molecular chaperone
able to promote either the association or the dissociation of
hTERT to hTR, depending on the cellular context.
Our results have broader implications considering the
antitelomerase action of retinoids and thereby their anti-
tumor properties independently of their effects on
differentiation: we propose that ATRA might target
telomerase through two distinct processes to ensure a sus-
tained inhibition of telomerase activity, first by decreasing
hTERT gene transcription and consequently the amount
of hTERT protein, and second, by increasing H19 level,
which in turn may impede telomerase assembly and func-
tions (Fig. 7). Further studies are required to fully eluci-
date the precise mechanisms by which H19 interfere with
the activity of the telomerase complex.
Conclusions
In conclusion, this study identifies for the first time a new
level of telomerase regulation through the involvement of
H19, and thereby reveals also a novel function for this
LncRNA in telomerase biology. It also suggests that dir-
ectly targeting hTERT/hTR complex through an increase
of H19 might provide a new treatment strategy for cancer
that could have clinical utility.
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